多期双能CT评估鼻咽癌诱导化疗反应
这项回顾性研究纳入294例鼻咽癌患者,分析多期双能CT定量参数与诱导化疗反应的关系,发现动脉期标准化碘浓度、动脉期强化分数和细胞外容积分数为独立预测因子,联合列线图预测反应AUC为0.803,在EB病毒DNA高低亚组及五种化疗方案亚组中AUC为0.761-0.833。
要点
- 动脉期标准化碘浓度、动脉期强化分数和细胞外容积分数是诱导化疗反应的独立预测因子。
- 联合列线图预测诱导化疗反应AUC为0.803(95%CI 0.740-0.864),优于各单独参数。
- 双能CT多期增强参数可无创预测诱导化疗反应,辅助筛选可能获益患者。
核心结论
- 整合动脉期标准化碘浓度、动脉期强化分数和细胞外容积分数的列线图可预测鼻咽癌诱导化疗反应,预测性能优于各单独参数。
研究设计与样本
- 回顾性研究,纳入2019年5月至2023年12月接受多期(平扫、动脉期、静脉期)双能CT增强扫描的鼻咽癌患者294例(中位年龄53岁,四分位距46-59岁,男224例),其中反应者215例、无反应者79例。
关键影像表现/征象
- 肿瘤动脉期标准化碘浓度(OR 0.71,95%CI 0.52-0.98,p=0.036)、动脉期强化分数(OR 1.45,95%CI 1.04-2.00,p=0.026)和细胞外容积分数(OR 0.65,95%CI 0.15-0.87,p=0.019)为化疗反应的独立预测因子。
诊断标准与关键数值
- 列线图预测诱导化疗反应在全部参与者中AUC=0.803(95%CI 0.740-0.864)。
- EB病毒DNA高亚组AUC=0.761,低亚组AUC=0.799。
- 五种不同化疗方案亚组AUC范围为0.773-0.833。
临床应用与阅片要点
- 多期双能CT定量参数可无创预测鼻咽癌诱导化疗反应,列线图有助于识别可能从诱导化疗中获益的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop a nomogram that assists in selecting nasopharyngeal carcinoma (NPC) patients suitable for induction chemotherapy.
MATERIALS AND METHODS: This retrospective study included NPC patients who underwent multiphasic contrast‑enhanced DECT (comprising non-contrast, arterial, and venous phase scanning) between May 2019 and December 2023. The relationships between quantitative DECT-derived parameters and treatment response to induction chemotherapy were analyzed using logistic regression analysis. The predictive performance of a nomogram integrating key predictors was assessed using the area under the receiver operating characteristic curve (AUC).
RESULTS: A total of 294 patients (median age, 53 years; interquartile range, 46-59 years; 224 men) were included. Among these, 215 were responders and 79 were non-responders. The normalized iodine concentration in the arterial phase (nICarterial) (odds ratio (OR), 0.71; 95% confidence interval (CI), 0.52-0.98; p = 0.036), arterial enhancement fraction (AEF) (OR, 1.45; 95% CI, 1.04-2.00; p = 0.026), and extracellular volume fraction (ECVf) (OR, 0.65; 95% CI, 0.15-0.87; p = 0.019) of tumors were identified as independent predictors of chemotherapy response. This nomogram demonstrated excellent performance (AUC = 0.803 [95% CI, 0.740-0.864]) across all participants, as well as in subgroup analyses of Epstein-Barr virus DNA (high and low) (AUC: 0.761, 0.799) and across five subgroups with different chemotherapy regimens (AUC, 0.773-0.833).
CONCLUSIONS: We developed a comprehensive nomogram to predict treatment response to induction chemotherapy by integrating nICarterial, AEF, and ECVf. This nomogram demonstrated superior predictive performance compared to the individual parameters when assessed separately.
KEY POINTS: Question To date, no reliable method has been established to predict the efficacy of induction chemotherapy for nasopharyngeal carcinoma prior to treatment. Findings nICarterial, AEF, and ECVf were the independent predictors of induction chemotherapy response, and the combined nomogram demonstrated strong performance to predict response. Clinical relevance The multiphasic contrast‑enhanced parameters derived from dual-energy CT offer a noninvasive approach to predict treatment response to induction chemotherapy and identify nasopharyngeal carcinoma patients who may benefit from induction chemotherapy.
引用
- Ren H, Huang J, Liu D, et al. Evaluation of induction chemotherapy response using multiphasic dual-energy CT in nasopharyngeal carcinoma. Eur Radiol. 2025. PMID: 40111492. doi:10.1007/s00330-025-11512-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。